Brief: Lee's Pharmaceutical Says Investigational New Drug Candidate Approved By U.S. FDA
09/11/2022 14:35
Nov 9 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* ON 26 OCT, INVESTIGATIONAL NEW DRUG CANDIDATE APPROVED BY
U.S.
FDA TO CONDUCT CLINICAL TRIAL IN U.S.
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA